deltatrials
Completed PHASE2 NCT00453180

A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

A Pilot Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

Sponsor: Indiana University School of Medicine

Conditions Asperger Syndrome Autistic Disorder Child Development Disorders, Pervasive
Interventions N-acetylcysteine Placebo
Updated 7 times since 2017 Last updated: May 19, 2017 Started: Mar 31, 2007 Primary completion: Aug 31, 2009 Completion: Nov 30, 2009

This PHASE2 trial investigates Asperger Syndrome and Autistic Disorder and is currently completed. Indiana University School of Medicine leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jul 2017 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Indiana University School of Medicine
  • National Alliance for Autism Research
Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Indianapolis, United States